- Conditions
- Glioblastoma
- Interventions
- Optune® device, Temozolomide, Pembrolizumab, Placebo
- Device · Drug
- Lead sponsor
- NovoCure GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 741 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 31 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Glioblastoma
- Interventions
- Poly-ICLC, Tumor Treating Fields, Peptides
- Drug · Device · Biological
- Lead sponsor
- Adilia Hormigo
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2029
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Glioblastoma, Glioma, Gliosarcoma
- Interventions
- Bevacizumab, TTFields Therapy
- Drug · Device
- Lead sponsor
- RTOG Foundation, Inc.
- Other
- Eligibility
- 22 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 11
- States / cities
- La Jolla, California • Orange, California • Miami, Florida + 8 more
- Conditions
- Glioblastoma
- Interventions
- Bevacizumab, PD-L1 t-haNK, N-803, Tumor Treating Fields (TTFields, 200 kHz)
- Drug · Device
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 4
- States / cities
- El Segundo, California • Fullerton, California • Newport Beach, California + 1 more
- Conditions
- Glioblastoma, Glioblastoma, WHO Grade IV
- Interventions
- Temozolomide (TMZ), Optune System, Pembrolizumab
- Drug · Device
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Recurrent Glioblastoma
- Interventions
- Pembrolizumab, Optune GIO®, NeuroBlate®
- Drug · Device
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Astrocytoma, Grade II, Astrocytoma, Grade III
- Interventions
- TTFields with adjuvant temozolomide
- Combination Product
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 5
- States / cities
- Gainesville, Florida • Tampa, Florida • Detroit, Michigan + 2 more
- Conditions
- Glioblastoma Multiforme
- Interventions
- Optune®
- Device
- Lead sponsor
- NovoCure Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 981 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 87
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 68 more